AstraZeneca has discontinued a phase III trial evaluating Epanova in patients with mixed dyslipidaemia who are at increased risk of cardiovascular (CV) disease due to its low likelihood of demonstrating any benefit.
The discontinuing of the trial follows a recommendation from an independent Data Monitoring Committee.
Phase III STRENGTH is a large-scale, global CV outcomes trial designed to evaluate the safety and efficacy of Epanova compared to placebo, both in combination with standard-of-care statin medicines.
“We are disappointed by these results, but we remain committed to addressing the needs of patients in the cardiovascular space where we have an extensive pipeline,” said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D.
“It was important to assess the potential benefit of Epanova in mixed dyslipidaemia
A review is being undertaken of the ongoing value of the $533 million Epanova intangible asset. Full data from the trial will be presented at a forthcoming medical meeting.